The synthetic lethality-based drugs and targets market is estimated to be worth USD 8 billion in 2030, predicts Roots Analysis Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit. For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html

In silico drug discovery services market is likely to be worth USD 124 million by 2030, growing at an annualized rate of 15.6%, claims Roots Analysis Owing to their cost and time saving potential, in silico tools are widely used in modern pharmacological research; several companies have developed novel tools, which are specifically designed to accelerate and augment the drug discovery process. For additional details, please visit https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html

The global autoinjectors market is projected to grow at an annualized rate of over 10%, till 2030 Autoinjectors have become an important part of modern healthcare, having demonstrated the potential to address a number of parenteral drug delivery related adverse events, and improve medication adherence among patients For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/autoinjectors-market/293.html

The outsourced cell therapy consumables market is projected to grow at a CAGR of 18% during 2021-2031, claims Roots Analysis Amidst the COVID-19 pandemic, there has been an evident surge in the demand for high quality cell therapies intended for research and therapeutic purposes, presenting lucrative opportunities for consumable providers having capabilities for raw material production For additional details, please visit https://www.rootsanalysis.com/reports/cell-therapy-consumables-market.html

The ADC Cytotoxic Payloads / Warheads market is anticipated to grow at a CAGR of 12.4% till 2030, claims Roots Analysis With six approved drugs, namely POLIVY™, LUMOXITI™, BESPONSA®, MYLOTARG™, KADCYLA®, ADCETRIS® and over 300 drugs underdevelopment, antibody drug conjugates (ADCs) have emerged as a promising class of targeted therapies for various disease indications. For additional details, please visit https://www.rootsanalysis.com/reports/adc-cytotoxic-payloads-market.html

The opportunity for AR / VR based digital marketing service providers in healthcare sector is projected to be worth USD 3 billion by 2030 at significant CAGR of 26% claims, Roots Analysis Given the present scenario, many stakeholders are adopting such advanced marketing strategies to drive better consumer engagement through the use of immersive and interactive technologies For additional details, please visit https://www.rootsanalysis.com/reports/view_document/healthcare-digital-marketing/323.html

SEVERAL ORGANIZATIONS HAVE EXTENDED FINANCIAL SUPPORT TO AID RESEARCH EFFORTS IN THIS DOMAIN Antibodies, also known as immunoglobulins, are Y-shaped glycoproteins that are produced by the immune system in response to foreign molecules (antigens) that enter the body. The term antigen refers to any substance that is capable of inducing an immune response; examples include viruses, fungi, bacteria, proteins on the surface of cells, and non-living substances, such as toxins For additional details, please visit https://www.rootsanalysis.com/reports/fc-protein-engineered-and-glycoengineered-antibodies-market.html

The Herceptin® biosimilars market is projected to witness considerable growth over the coming years Herceptin® sales peaked in 2018, a year before the primary patent covering the drug expired in the US; in order to carve out a share of the associated opportunity, stakeholders in the pharma industry have long been developing follow on products For additional details, please visit https://www.rootsanalysis.com/reports/biopharmaceutical-cros-market.html

The Herceptin® biosimilars market is projected to witness considerable growth over the coming years Herceptin® sales peaked in 2018, a year before the primary patent covering the drug expired in the US; in order to carve out a share of the associated opportunity, stakeholders in the pharma industry have long been developing follow on products For additional details, please visit https://www.rootsanalysis.com/reports/biopharmaceutical-cros-market.html